# A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)

> **NCT07663318** · PHASE1 · COMPLETED · sponsor: **Triastek (Shanghai) Limited** · enrollment: 18 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** T25-Fast
- **DRUG:** Mycapssa
- **DRUG:** T25-Fed

## Key facts

- **NCT ID:** NCT07663318
- **Lead sponsor:** Triastek (Shanghai) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-06-25
- **Primary completion:** 2026-07-22
- **Final completion:** 2026-07-24
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663318, "A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07663318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*